^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TP53-EphA-2-CAR-DC

    i
    Other names: TP53-EphA-2-CAR-DC, autologous EphA2-targeting CAR-DC vaccine loaded with TP53 mutant peptide
    Associations

    News

    Trials
    Company:
    Chinese PLA General Hospital
    Drug class:
    Dendritic cell activator, EphA2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    Combination of CAR-DC Vaccine and ICIs in Malignant Tumors (clinicaltrials.gov)
    P1, N=10, Recruiting, Chinese PLA General Hospital | Initiation date: Feb 2023 --> Jul 2023
    Trial initiation date • IO biomarker • Metastases
    |
    TP53 (Tumor protein P53) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
    |
    PD-L1 expression • TP53 mutation • MSI-H/dMMR • TP53 R175H • TP53 R248Q • TP53 R273H
    |
    Yervoy (ipilimumab) • albumin-bound paclitaxel • cyclophosphamide • TP53-EphA-2-CAR-DC
    almost2years
    Combination of CAR-DC Vaccine and Anti-PD-1 Antibody in Malignant Tumors (clinicaltrials.gov)
    P1, N=10, Recruiting, Chinese PLA General Hospital | N=20 --> 10
    Enrollment change • IO biomarker • Metastases
    |
    TP53 (Tumor protein P53) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
    |
    PD-L1 expression • TP53 mutation • MSI-H/dMMR • TP53 R175H • TP53 R248Q • TP53 R273H
    |
    albumin-bound paclitaxel • cyclophosphamide • TP53-EphA-2-CAR-DC
    2years
    Combination of CAR-DC Vaccine and Anti-PD-1 Antibody in Malignant Tumors (clinicaltrials.gov)
    P1, N=20, Recruiting, Chinese PLA General Hospital
    New P1 trial • IO biomarker • Metastases
    |
    TP53 (Tumor protein P53) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
    |
    PD-L1 expression • TP53 mutation • MSI-H/dMMR • TP53 R175H • TP53 R248Q • TP53 R273H
    |
    albumin-bound paclitaxel • cyclophosphamide • TP53-EphA-2-CAR-DC